Literature DB >> 35652548

PSA density is associated with BPH cellular composition.

Liwei Jia1, Douglas W Strand2, Ramy S Goueli2, Jeffrey C Gahan2, Claus G Roehrborn2, Ryan J Mauck2.   

Abstract

BACKGROUND: Current AUA guidelines recommend 5 alpha reductase inhibitor (5ARI) treatment for patients with obstructive benign prostatic hyperplasia (BPH) that display prostate volume ≥30 cc and total prostate specific antigen (PSA) ≥1.5 ng/ml. However, BPH is highly pleomorphic and response to 5ARIs is highly variable. An understanding of cellular composition based on a noninvasive PSA density test could lead to improved clinical decision making.
METHODS: The histological composition of 307 BPH specimens was scored by a pathologist for stromo-glandular content and associated with total PSA, prostate volume, PSA density and other clinical variables using univariate and multivariate linear regression.
RESULTS: The percentage of glandular composition in prostates of 5ARI-naïve men was positively and independently associated with PSA and PSA density. It was determined through statistical modeling that a PSA density ≤0.05 ng/ml2 associated with a glandular composition of ≤30% with 76% sensitivity.
CONCLUSIONS: PSA density could provide a decisive variable for estimating BPH cellular content and may eventually improve selection of patients for 5ARI treatment. Further work is needed to demonstrate that patients with higher glandular content are more responsive to 5ARI treatment.
© 2022 Wiley Periodicals LLC.

Entities:  

Keywords:  PSA density; benign prostatic hyperplasia; histology; prostate specific antigen; prostate volume

Mesh:

Substances:

Year:  2022        PMID: 35652548      PMCID: PMC9329225          DOI: 10.1002/pros.24367

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.012


  11 in total

Review 1.  Targeting phenotypic heterogeneity in benign prostatic hyperplasia.

Authors:  Douglas W Strand; Daniel N Costa; Franto Francis; William A Ricke; Claus G Roehrborn
Journal:  Differentiation       Date:  2017-08-04       Impact factor: 3.880

2.  Treatment of chronic prostatitis lowers serum prostate specific antigen.

Authors:  Caleb B Bozeman; Brett S Carver; James A Eastham; Dennis D Venable
Journal:  J Urol       Date:  2002-04       Impact factor: 7.450

3.  Origin and evolution of benign prostatic enlargement.

Authors:  J E McNeal
Journal:  Invest Urol       Date:  1978-01

4.  The relative amount of epithelium, muscle, connective tissue and lumen in prostatic hyperplasia as a function of the mass of tissue resected.

Authors:  G A Schuster; T G Schuster
Journal:  J Urol       Date:  1999-04       Impact factor: 7.450

5.  MRI Features Associated with Histology of Benign Prostatic Hyperplasia Nodules: Generation of a Predictive Model.

Authors:  Jessica C Dai; Tara N Morgan; Ramy Goueli; Daniel Parrott; Alexander Kenigsberg; Ryan J Mauck; Claus G Roehrborn; Douglas W Strand; Daniel N Costa; Jeffrey C Gahan
Journal:  J Endourol       Date:  2022-02-28       Impact factor: 2.619

6.  Evolving patterns of tissue composition in benign prostatic hyperplasia as a function of specimen size.

Authors:  H Price; J E McNeal; T A Stamey
Journal:  Hum Pathol       Date:  1990-06       Impact factor: 3.466

7.  The response to alpha blockade in benign prostatic hyperplasia is related to the percent area density of prostate smooth muscle.

Authors:  E Shapiro; V Hartanto; H Lepor
Journal:  Prostate       Date:  1992       Impact factor: 4.104

8.  The effect of acute urinary retention on serum prostate-specific antigen level.

Authors:  Majeed Aliasgari; Mohammad Soleimani; Seyyed Mohammadmehdi Hosseini Moghaddam
Journal:  Urol J       Date:  2005       Impact factor: 1.510

9.  Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA GUIDELINE PART II-Surgical Evaluation and Treatment.

Authors:  Lori B Lerner; Kevin T McVary; Michael J Barry; Brooke R Bixler; Philipp Dahm; Anurag Kumar Das; Manhar C Gandhi; Steven A Kaplan; Tobias S Kohler; Leslie Martin; J Kellogg Parsons; Claus G Roehrborn; John T Stoffel; Charles Welliver; Timothy J Wilt
Journal:  J Urol       Date:  2021-08-13       Impact factor: 7.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.